# Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

> **NCT04827589** · PHASE2 · WITHDRAWN · sponsor: **Gilead Sciences**

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Tirabrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04827589
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07
- **Primary completion:** 2022-04
- **Final completion:** 2022-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development program terminated
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827589, "Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04827589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*